Placebo Orthodoxy in Clinical Research II: Ethical,Legal,and Regulatory Myths

Rothman K.J. Michels K.B. , “The Continuing Unethical Use of Placebo Controls,” N. Engl. J. Med., 331 (1994): 394–98.

Declaration of Helsinki (Helsinki: 18th World Medical Assembly, 1964; rev., Tokyo: 29th World Medical Assembly, 1975; rev., Venice, 35th World Medical Assembly, 1983; rev., Hong Kong: 41st World Medical Assembly, 1989; rev., Somerset West, South Africa, 48th General Assembly, 1996): At II.3. The 1996 revision added the following sentence to II.3. “This does not exclude the use of inert placebo in studies where no proven diagnostic or therapeutic method exists.”

Lasagna L. , “The Helsinki Declaration: Timeless Guide or Irrelevant Anachronism?,” Journal of Clinical Psychopharmacology, 2(1995): 96–98.

Council for International Organizations of Medical Sciences, International Ethical Guidelines for Biomedical Research Involving Human Subjects (Geneva: World Health Organization, 1993): At 52.

Freedman B. , “Placebo Controlled Trials and the Logic of Clinical Purpose,” IRB: A Review of Human Subjects Research, 1, no. 6 (1990): 1–6.

Medical Research Council of Canada, Guidelines on Research Involving Human Subjects (Ottawa: Minister of Supply & Services, 1987).

American Medical Association, “Ethical Guidelines for Clinical Investigation, 1966,” in Reich W.T. , ed., Encyclopedia of Bioethics (New York: Free Press, vols. 3, 4, 1978): 1773–74.

Rickels K. , “Use of Placebo in Clinical Trials?,” Psychopharmacology Bulletin, 22, no. 1 (1986): 19–24; and Klerman G.L. , “Scientific and Ethical Considerations in the Use of Placebo Controls in Clinical Trials in Psychopharmacology,” Psychopharmacology Bulletin, 22, no. 1 (1986): 25–29.

Pohl R. Baron R. , letter; comment; discussion, “The Use of Placebo Controls,” N. Engl. J. Med., 332 (1995): 61–62.

Levine R. , oral comment, Public Responsibility in Medicine & Research Conference, Nov. 1, 1994.

Lasagna , supra note 4.

Temple R. , “Government Viewpoint of Clinical Trials,” Drug Information Journal, Jan./Feb. (1982): 10–17.

Levine R.J. , “The Use of Placebos in Randomized Clinical Trials,” IRB: A Review of Human Subjects Research, 7, no. 2 (1985): 1–4.

Clery D. , “Use of Placebo Controls in Clinical Trials Disputed,” Science, 267 (1995): 2–26.

Freedman B. , “Ethics and Placebo-Controlled Thrombolytic Trials: The Future,” Coronary Artery Disease, 2 (1991): 849–52; Geraci E. , “Enrolment in Trials of Thrombolysis,” Lancet, 336 (1990): 1069–70; and Brody B.A. , Ethical Issues in Drug Testing, Approval, and Pricing (New York: Oxford University Press, 1995): Ch. 2.

Curson D.A. , “Does Short Term Placebo Treatment of Chronic Schizophrenia Produce Long Term Harm?,” British Medical Journal (Clinical Research Edition), 293 (1986): 726–28.

National Institutes of Health, Office for Protection from Research Risks, Protecting Human Subjects: Institutional Review Board Handbook (Washington, D.C.: U.S. Government Printing Office, 1993): At 4–23.

Picard E. , Legal Liability of Doctors and Hospitals in Canada (Toronto: Carswell, 2nd ed., 1994); and Prosser W. Keaton W. , The Law of Torts (St. Paul: West, 5th ed., 1984).

Halushka v. University of Saskatchewan, (1965) 93 D.L.R. 2d 436; and Kus v. Sherman Hospital, 644 N.E.2d 1214 (Ill. App. 1995).

Mason J.K. McCall-Smith R.A. , Law & Medical Ethics (London: Butterworth, 2nd ed., 1987); Giesen D. , International Medical Malpractice Law (Dordrecht: Nijhoff, 1988): At § 48, para. 1200; and Baudouin J.-L. , “L'Experimentation sur les Humains: Un Conflit de Valeurs,” McGill Law Journal, 26 (1986): 809–46.

Simmons L. , “Problems in Deceptive Medical Procedures: An Ethical and Legal Analysis of the Administration of Placebos,” Journal of Medical Ethics, 4 (1978): 172–81; Kapp M.B. , “Placebo Therapy & the Law: Prescribe with Care,” American Journal of Law & Medicine, 8 (1983): 371–405; Mason McCall-Smith , supra note 23; Giesen , supra note 23; and Baudouin , supra note 23.

Mason Smith McCall , supra note 23; and Giesen , supra note 23,

Halushka, 93 D.L.R. 2d at 436; and Sherman Hospital, 644 N.E.2d at 1214.

Prosser Keaton , supra note 21, at § 68.

Kennedy I. Grubb I. , Medical Law: Text and Materials (London: Butterworth, 1989): At 452; and Perry C.B. , “Conflicts of Interest and the Physician's Duty to Inform,” American Journal of Medicine, 96 (1994): 375–80.

Giesen , supra note 23, § 46, para. 1200.

Prosser Keaton , supra note 21, at §§ 106–07; and Perry , supra note 28.

Mason McCall-Smith , supra note 23.

Giesen , supra note 23.

Clery , supra note 15.

45 C.F.R. § 46.111(a)(2) (1991).

Appelbaum P.S. Litz C.W. Meisel A. , Informed Consent: Legal Theory and Clinical Practice (New York: Oxford University Press, 1987): At 60–62.

Faden R. Beauchamp T. , A History and Theory of Informed Consent (New York: Oxford University Press, 1986): At 274, 287–94.

Lidz C.W. , Informed Consent: A Study of Decisionmaking in Psychiatry (New York: Guilford Press, 1984): At 235.

National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, “The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research,” OPRR Reports, Apr. 18 (1979): 1–8; and Ratzan R. , “Being Old Makes You Different: The Ethics of Research with Elderly Subjects,” Hastings Center Report, 10, no. 5 (1980): 32–46.

Picard , supra note 21, at 61, 119.

Baker C.D. , Tort (London: Sweet & Maxwell, 2nd ed., 1976): At 52; and Kennedy Grubb , supra note 28, at 279.

Prosser Keaton , supra note 21, at § 68.

Kapp , supra note 24.

Food, Drug, and Cosmetic Act of 1938, 52 Stat. 1040, 21 U.S.C. §§ 301 et seq. at § 505(d) (as amended 1962).

21 C.F.R. § 314.26(b)(2) (1991).

“Investigation of Drugs in Humans; Availability of Guidelines,” 44 Fed. Reg. 20,796 (1979).

“Guidelines for the Conduct of Clinical Trials: FDA Guidelines for Psychotropic Drugs,” Psychopharmacology Bulletin, 1, no. 4 (1974): 70–91; and “FDA Guidelines for the Clinical Evaluation of Psychotropic Drugs—Antidepressant and Antianxiety Drugs,” Psychopharmacology Bulletin, 14, no. 2 (1978): 45–63.

“FDA Guidelines,” supra note 46.

“Guidelines for the Conduct of Clinical Trials,” supra note 46.

“Investigation of Drugs in Humans,” supra note 45.

“Guidelines for the Conduct of Clinical Trials,” supra note 46.

21 C.F.R. § 314.26(b)(2)(iv) (1991).

Ballin J.C. , “Who Makes the Therapeutic Decisions?,” JAMA, 242 (1979): 2875.

Hutt P.B. Merrill R.A. , Food and Drug Law (Westbury: Foundation Press: 1991): At 528n.

44 Fed. Reg. 51,512 (Aug. 31, 1979).